Research Analysts’ Weekly Ratings Updates for Rapport Therapeutics (RAPP)

Several analysts have recently updated their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 8/5/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 7/28/2026 – Rapport Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
• 7/17/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 6/24/2026 – Rapport Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $52.00 price target on the stock.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction on Monday, July 27th. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10. Following the completion of the sale, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at $22,638,630.77. The trade was a 0.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Rock Ventures V. L.P. Third sold 271,495 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $40.12, for a total value of $10,892,379.40. Following the completion of the sale, the insider owned 6,437,733 shares of the company’s stock, valued at $258,281,847.96. This represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 430,913 shares of company stock worth $17,308,315. 12.48% of the stock is owned by insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.